Pseudomonas aeruginosa in the ICU: prevalence, resistance profile, and antimicrobial consumption
AUTOR(ES)
Ribeiro, Ághata Cardoso da Silva
FONTE
Rev. Soc. Bras. Med. Trop.
DATA DE PUBLICAÇÃO
20/12/2019
RESUMO
Abstract INTRODUCTION: Pseudomonas aeruginosa is one of the main pathogens causing infection in intensive care units (ICUs) and usually presents antimicrobial resistance. METHODS: Data were obtained from ICUs between 2010 and 2013. RESULTS: P. aeruginosa had a prevalence of 14.5% of which 48.7% were multidrug resistant. We observed increasing resistance to carbapenems and polymyxin B and growing consumption of aminoglycosides, meropenem, ceftazidime, and polymyxin B. The regression impact between resistance and consumption was significant with respect to amikacin, imipenem, meropenem, and polymyxin B. CONCLUSIONS: Monitoring antimicrobial consumption and resistant microorganisms should be reinforced to combat antimicrobial- and multi-drug resistance.
Documentos Relacionados
- Antimicrobial catheters in the ICU: is the juice worth the squeeze?
- Staphylococcus aureus in tonsils of patients with recurrent tonsillitis: prevalence, susceptibility profile, and genotypic characterization
- Shigella in Brazilian children with acute diarrhoea: prevalence, antimicrobial resistance and virulence genes
- Salmonella spp. prevalence, antimicrobial resistance and risk factor determination in Colombian swine farms
- Cellular Fatty Acid Composition, Soluble-Protein Profile, and Antimicrobial Resistance Pattern of Eubacterium lentum